SCHEMBL31444482

SCHEMBL31444482

CC(C)(C)OC(=O)N1CC(O)CC1c1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
PDE5A O76074 1/20 0.41
TSHR P16473 2/20 0.40
NR1H2 P55055 3/20 0.39
STS P08842 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
GRM5 P41594 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
EGFR P00533 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31419219 0.85 ROCK2 (0.47) RIPK1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL23064594 0.85 RIPK1 (0.43) RIPK1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL31444298 0.83 ROCK2 (0.38) PDE5ATSHRNR1H2STSALDH1A1
SCHEMBL30078453 0.83 CYP1A2 (0.42) RIPK1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL38659898 0.82 RIPK1 (0.64) RIPK1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL4035098 0.82 RIPK1 (0.64) RIPK1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL4035101 0.82 RIPK1 (0.64) RIPK1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL28234024 0.82 RIPK1 (0.64) RIPK1CYP1A2POLBCYP3A4CYP2C19
SCHEMBL27139334 0.80 RIPK1 (0.44) RIPK1PDE5AGRM5HSP90AA1HSP90AB1
SCHEMBL31444419 0.80 TSHR (0.55) RIPK1TSHRSTSALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072451-A1 RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES VIVIDION THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed